Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Lurbinectedin in BRCA 1/2 breast cancer

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.10.16
Views: 2469
Rating:

Dr Judith Balmaña - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Dr Balmaña speaks with ecancer at ESMO 2016 about using lurbinectedin, a trabectidin analogue, in the treatment of breast cancer.

She describes its mechanism of action, aiming to use the resulting gene suppression and DNA damage selectively in tumour cells, and gives results of progression-free and overall survival among multiple patient cohorts.

Dr Balmaña outlines further research into the timing and exposure factors that may influence patient response to lurbinectedin, especially PARP inhibitors, and studies of its activity in other tumour sites.

Lurbinectedin was discussed further by Dr Cristina Cruz as a possible course of treatment in PARP inhibitor resistant patients.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation